Peter Kong, CFA

peter.kong@clsa.com +60 3 2056 7877

6 October 2017

Malaysia

Infrastructure

Reuters Bloomberg SCOG.KL SCGB MK

Priced on 5 October 2017 KLSE Comp @ 1,759.1

12M hi/lo RM2.36/1.59

12M price target RM2.80 +22% ±% potential

1,292.9m Shares in issue 45.6% Free float (est.)

US\$703m Market cap

3M average daily volume RM3.7m (US\$0.9m)

Foreign s'holding 9.0%

Major shareholders

Sunway Berhad 54.4% Sungei Way Corp Sdn Bhd 10.1%

Stock performance (%)

	1M	3M	12M
Absolute	0.4	15.0	37.7
Relative	1.0	15.6	30.2
Abs (US\$)	1.5	16.9	34.4
2.5 (RM)		(%)	200
2.2 -	المساولان سيامد	الريديان الإسمارات	- 150
1.9-		ليهام أداد	- 100
1.7- MM.	ppendlygge	A PARTY	
1.4			- 50
1.1	1	-	
Oct-15 Apr-16	Oct-16	Apr-17	
	SunCon (LI Rel to Com		
Source: Bloomber	g		

www.clsa.com

The rail deal

Largest-ever project of RM2.2 billion; quidance exceeded

SunCon has won a large RM2.2 billion award for Light Rail Transit Line 3 (LRT3), and the sheer magnitude that its RM2 billion job win guidance for 2017 has now been surpassed (YTD win of RM3.8 billion) should be convincingly positive. Propelling its order book to a lofty RM6.5 billion, this win not only enhances visibility as some projects complete in 2018, but also cements credentials for future prospects, namely the East Coast Rail Line (ECRL) and the High Speed Rail (HSR) where it may participate. This larger-than-expected award forms 17%/22% of EPS for 18CL/19CL and we slightly raise our TP to RM2.80 (from RM2.75) and stay Buyers.

Smashes SunCon's own job win guidance; extends visibility

A 3rd award by Prasarana in recent years, this package clinched by SunCon is its largest award ever, bringing the YTD job win tally to RM3.75 billion - ahead of its peers, and far exceeding SunCon's guidance and our expectation of RM2 billion and RM2.2 billion, respectively. Crucially, it extends visibility as several key projects, namely Putrajaya parcel F, Sunway Medical Center 4, KLCC and International School of Kuala Lumpur (combined estimated 38% of its order book previous to this win) would be completing by 2018.

Its 4th elevated rail job since 2011 lowers risk; slight margin trim

Credentials in rail projects, namely the LRT, mass and bus rapid transit (MRT & BRT) lines mitigate execution risk. Nevertheless, we bake in pretax margins of a slimmer 6% (8% expected previously) given the timeline (36 months), a well-populated area for construction and a cable-stayed bridge over a river (not SunCon's forte). On balance, the rise of steel prices (about 30% over the past 3 months) is manageable as it forms only a small portion of costs.

Likely to throw hat in the ring for ECRL and HSR

Guidance for 2018 has not been revealed but the ECRL and HSR could feed into the pipeline of rail-related jobs for SunCon over the next 18 months. Inhouse jobs to date sum up to RM453 million (12%), and we should be able to count on hospital jobs from its parent for padding up orders.

Maintain BUY. Mild nudge up of TP to RM2.80

Amid the better-than-expected job win, the ramp-up in earnings in 18CL shows its PE multiples will compress to 13.8x (peer average: 14.7x). Factoring in incremental profits from this award compared to our expectation raises our TP to RM2.80, which translates to a TSR of 25%.

Financials

Year to 31 December	15A	16A	17CL	18CL	19CL
Revenue (RMm)	1,917	1,789	2,380	3,304	3,488
Rev forecast change (%)	-	-	2.5	16.4	20.4
Net profit (RMm)	127	124	154	216	229
NP forecast change (%)	-	-	(1.9)	2.7	3.1
EPS (sen)	9.8	9.6	11.9	16.7	17.7
CL/consensus (12) (EPS%)	-	-	103	129	127
EPS growth (% YoY)	39.4	(2.9)	24.6	40.4	6.1
PE (x)	23.4	24.1	19.3	13.8	13.0
Dividend yield (%)	1.7	2.2	3.3	3.7	3.9
ROE (%)	30.6	26.2	29.5	35.8	32.2
Net debt/equity (%)	(56.2)	(66.7)	(65.0)	(72.9)	(70.4)

Source: CLSA




Largest ever job win; order book boosted to new heights This award, package GS07-08 for LRT3, is SunCon's 4th rail-related award since 2011, following the clinching of parcels for MRT Line 1 (RM1.17 billion) in 2012, bus rapid transit (RM0.45 billion) in 2013, and more recently the MRT Line 2 for RM1.21 billion. Representing its largest job win ever, its outstanding order book is propelled to RM6.5 billion from RM4.7 billion previously. By source, external jobs dominated 88% of total wins to date. YTD, total job awards far exceeded its own guidance of RM2 billion and also beats ours of RM2.2 billion.

Figure 1

Outstanding order book and annual new jobs 7.0 6.5 Average 6.0 replenisment: RM2.4 billion 5.0 3.8 =4.0 3.2 3.0 ≥ ≃3.0 2.7 2.6 1.9 2.0 0.8 1.0 0.0 2012 2013 2014 2015 2016 YTD 2017

Figure 2



Source: CLSA, SunCon

Source: CLSA, SunCon

Cable-stayed bridge a unique feature compared to previous undertakings; SunCon is charged to complete 9.2 kilometers of viaducts in Klang (from Kawasan 17 to Sri Andalas) and 6 stations, among others (refer figure 3 & 4). Aside the longer viaduct (compared to SunCon's 4.9 kilometers entrusted under MRT Line 2), a key difference compared to previous undertakings take the form of a cable-stayed bridge that would run across the Klang River. While this is a design and build component – which normally fetches better margin – we note that bridges are beyond SunCon's usual forte.

Figure 3

Scope of SunCon's undertaking for package GS07-08

9.2 km of viaduct works

6 station works

1 cable-stayed bridge over Klang River (design & build)

2 Park & Ride at Pasar Besar Klang and Sri Andalas

1 centralised labour quarters at Johan Setia

Source: CLSA



Figure 4

LRT3 alignment - red section shows SunCon's stretch



Red Line above denotes our proposed 9.2km alignment

Source: SunCon

Timeliness risk but has experience coordinating multiple large projects

Factor in more-modest margins for the risk of this larger undertaking

Steel price jump not seen to be an issue

To be completed in 36 months, SunCon is set to pencil in RM2.2 billion of top line over that time frame. While the short timeline to complete the task may pose a challenge, we think that execution risk is mitigated by the fact that SunCon had in the past proven that it was able to concurrently handle the Light Rail Transit, BRT and MRT Line 1 projects.

SunCon's strategy for LRT3 was to submit a few bids and it has done well to bag the biggest package announced to-date under LRT3 for viaduct awards. Considering the tight timeline, the need to build through a more-populated area, and some additional capital expenditure, we nevertheless capture the risk by estimating a pre-tax profit margin of a more modest 6%; this compares against the 8.1% and 9.4% construction margins seen in 1Q17 and 2Q17 respectively.

On balance, although the jump in construction steel over the past 3 months up to end-September 2017 have been steep (estimated to be circa 30%), and that the LRT3 project award does not contain a pass-through clause for steel price (such as seen in the MRT projects), the percentage contribution of steel into overall project cost is understood to be small (in the single digits).

Prepared for - W: peter.kong@clsa.com



Figure 3

Comparison of viaduct packages awarded under LRT3								
Company	Package	Job size (RM billion)	Length (Kilometers)	Value per kilometer (RM billion)	Remarks			
SunCon	GS07-08	2.18	9.2	*	6 stations. From Kawasan 17 to Sri Andalas			
Gabungan AQRS (Not rated)	GS04	1.14	4.5	0.25	-			
WCT Holdings Berhad (Not rated)	GS02	0.64	2.9	0.22	Merchant Square to Suria Damansara			
WCT	GS03	0.84	2.8	0.30	Suria Damansara to Temasya Glenmarie			

Source: CLSA

Amounts to RM240 million per KM; this is comparable to its MRT line 2 award While the value of the package clinched by SunCon towers over the rest of the packages so far awarded to other contractors, the value per kilometer basis is fairly comparable (refer figure 4). In addition, it also stacks up with SunCon's package V201 under MRT Line 2, at a value of RM1.21 billion for a length of 4.9 kilometers (equivalent to c.RM250 million per kilometer).

Figure 4


rigure 4		
SunCon's job wins this year -RM3.8 billion		
Contract	Duration	Contract Sum (RM mil)
LRT3: package GS07-08	Q4 2020	2,178
PPA1M project in Kota Bharu	1Q 2020	582
Sunway Serene	4Q 2020	449
MRT 201	4Q 2020	212
Gas District Cooling (GDC) 1	3Q 2018	152
Precast	-	98
SUKE and DASH highway	1H 2018	34
Bukit Bintang City Center (piling)	1Q 2018	34
Mega Capital (piling)	4Q 2017	9
CP3 walkway	3Q 2017	4
Total		3,752

Source: CLSA, SunCon

SunCon is in pole position Y

for YTD job wins when juxtaposed against selection of listed peers

YTD job wins for selected construction peers



Source: CLSA, companies

Trading above sector average but PE multiple will compress in 18CL Smashing expectations on job wins this year, we remain **BUYERS** of SunCon. Having cemented further its credentials in rail-related jobs with this win,



SunCon stands in good stead to participate in future projects such as the ECRL and the HSR, in additional to in-house job prospects from its parent.

This larger-than-predicted award is envisaged to make up 2/3 cents for EPS of 18CL/19CL. Trading at 19.3x PE for 17CL, the earnings growth in 18CL will compress the multiples quickly. We continue to price SunCon at 16.7x PE for 18CL, deriving a slightly raised target price of RM2.80 (from RM2.75).

Trading at 0.9 sd above mean PE since listing, but justified by a surge in order book

Figure 6



Source: CLSA

Figure 7

Summary of changes to PATMI						
RM mil	Previous	Revised	Variance	Remark		
17CL	157	154	(3)	Later than expected LRT3 award; lowered margin expectation		
18CL	210	216	6	Increment from larger-than-expected award		
19CL	222	229	7			

Source: CLSA

Valuation details

We value SunCon using the price-earnings multiple approach. Its target price is derived from 16.7x 18CL earnings, which is based on 1sd above the 3-year construction sector mean forward PE ratio; this is still below the same ratio for heavyweights Gamuda and IJM, but above its mid-cap peers. We accord premium valuations over mean in our calculations to reflect its robust ROEs of more than 20%, strong cashflow generation backed by steady job orders from both internal and external sources. We further note that in our valuations, we have not incorporated benefit from its consistent net cash position.

Investment risks

The investment risks for SunCon mainly stem from construction risk. Specific risk to our estimates would be lower-than-expected margins (below 5-8%) or amount of projects secured falls below our expectation, either due to inability to secure projects or caused by delay on project roll-out. The increase in steel prices beyond anticipated will also creep into margins as SunCon hedges steel needs for a future 6-month period. On the pre-cast segment, risks to our earnings will be erosion of its currently-strong margins of 20% and/or the inability to retain customers due to the shift in its plant location (from Singapore to Malaysia) causing a slowdown in orders. SunCon is also susceptible to risk facing the construction industry in general, which includes



the risk of disputes and ensuing lengthy negotiations which is not uncommon, not to mention the fluctuations in raw materials and availability of labour.





Summary	/ tipo	ncialc
Summer		III.IAIS
ounning:	, , , , , ,	

Year to 31 December	2015A	2016A	2017CL	2018CL	2019CL
Summary P&L forecast(RMm					
Revenue	1,917	1,789	2,380	3,304	3,488
Op Ebitda	178	188	245	329	349
Op Ebit	136	149	186	263	277
Interest income	8	10	12	12	15
Interest expense	(4)	(6)	(5)	(5)	(5)
Other items	-	0	-	-	-
Profit before tax	141	154	193	270	287
Taxation	(13)	(30)	(39)	(54)	(57)
Minorities/Pref divs	(1)	0	0	0	C
Net profit	127	124	154	216	229
Summary cashflow forecast (RMm)				
Operating profit	136	149	186	263	277
Operating adjustments	(3)	(22)	0	0	C
Depreciation/amortisation	42	39	59	66	72
Working capital changes	65	(59)	(42)	(6)	(77)
Net interest/taxes/other	(8)	(33)	(39)	(54)	(57)
Net operating cashflow	232	75	165	269	215
Capital expenditure	(39)	(19)	(45)	(45)	(45)
Free cashflow	193	56	120	224	170
Acq/inv/disposals	40	13	-	-	
Int, invt & associate div	(57)	89	12	12	15
Net investing cashflow	(56)	83	(33)	(33)	(30)
Increase in loans	2	0	-	-	-
Dividends	(70)	(84)	(97)	(110)	(116)
Net equity raised/other	0	-	0	0	C
Net financing cashflow	(68)	(84)	(97)	(110)	(116)
Incr/(decr) in net cash	107	74	35	126	69
Exch rate movements	5	2	(5)	(6)	(5)
Opening cash	278	390	465	495	616
Closing cash	390	465	495	615	679
Summary balance sheet foreca	act (PMm)				
Cash & equivalents	390	466	495	616	679
Debtors	579	732	796	1,104	1,166
Inventories	17	24	0	0	1,100
Other current assets	230	220	233	233	233
Fixed assets	162	138	125	104	77
Intangible assets	4	6	6	6	6
Other term assets	14	11	11	11	11
Total assets	1,397	1,597	1,665	2,074	2,171
Short-term debt	137	137	137	137	137
Creditors	796	955	977	1,280	1,264
Other current liabs	9	11	-	-	1,20
Long-term debt/CBs	_		_	_	
Provisions/other LT liabs	4	1	1	1	1
Minorities/other equity	1	1	1	1	1
Shareholder funds	451	493	550	656	770
Total liabs & equity	1,397	1,597	1,665	2,074	2,172
	,	,	,	, -	,
Ratio analysis	4.0	(6.7)	22.4	20.0	
Revenue growth (% YoY)	1.9	(6.7)	33.1	38.8	5.6
Ebitda growth (% YoY)	10.2	5.7	30.0	34.3	6.1
Ebitda margin (%)	9.3	10.5	10.3	10.0	10.0
Net profit margin (%)	6.6	6.9	6.5	6.5	6.6
Dividend payout (%)	40.6	52.3	62.9	50.8	50.7
Effective tax rate (%)	9.2	19.5	20.0	20.0	20.0
Ebitda/net int exp (x)	-	-	-	-	/===
Net debt/equity (%)	(56.2)	(66.7)	(65.0)	(72.9)	(70.4
ROE (%)	30.6	26.2	29.5	35.8	32.2
DOIC (0/)	EO 1	CE E	63.3	113.4	108.9
ROIC (%) EVA®/IC (%)	59.1 48.2	65.5 54.6	83.2 72.3	102.5	98.0

Source: CLSA





Research subscriptions

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email_alert/.


Companies mentioned

SunCon (SCGB MK - RM2.30 - BUY) Gamuda (GAM MK - RM5.25 - U-PF) Hock Seng Lee (N-R) IJM (IJM MK - RM3.24 - O-PF) Mudajaya (N-R) TRC Synergy (N-R) WCT (N-R)

Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.

Important disclosures



Source: CLSA

The policy of CLSA (which for the purpose of this disclosure includes its subsidiary CLSA B.V.) and CL Securities Taiwan Co., Ltd. ("CLST") is to only publish research that is impartial, independent, clear, fair, and not misleading. Analysts may not receive compensation from the companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read

in conjunction with the research disclaimer as set out at www.clsa.com/disclaimer.html and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of a discloseable position should not be taken as endorsement on the validity or quality of the research report or recommendation.



To maintain the independence and integrity of CLSA's research, our Corporate Finance, Sales Trading and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA Corporate Finance (or "investment banking") department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management.

CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading and Research activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

Unless specified otherwise, CLSA/CLST did not receive investment banking/non-investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, CLSA/CLST does not own a material discloseable position, and does not make a market, in the securities.

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other

relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, nonpublic information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF: Total expected return below 20% but exceeding market return; U-PF: Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

We define as "Double Baggers" stocks we expect to yield 100% or more (including dividends) within three years at the time the stocks are introduced to our "Double Bagger" list. "High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA/CLST only Universe:

Overall rating distribution: BUY / Outperform - CLSA: 64.86%; CLST only: 59.09%, Underperform / SELL - CLSA: 35.14%; CLST only: 40.91%, Restricted - CLSA: 0.00%; CLST only: 0.00%. Data as of 30 September 2017.

Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 4.31%; CLST only: 0.00%, Underperform / SELL - CLSA: 3.33%; CLST only: 0.00%, Restricted - CLSA: 0.00%; CLST only: 0.00%. Data for 12-month period ending 30 September 2017.

There are no numbers for Hold/Neutral as CLSA/CLST do not have such investment rankings.

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: (a) CLSA, Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; (b) CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682,

9

Prepared for - W: peter.kong@clsa.com



Taiwan, telephone (886) 2 2326 8188). © 2017 CLSA Limited and/or CLST.

© 2017 CLSA Limited, and/or CL Securities Taiwan Co., Ltd. ("CLST")

This publication/communication is subject to and incorporates the terms and conditions of use set out on www.clsa.com website the (www.clsa.com/disclaimer.html.). Neither the publication/communication nor any portion hereof may reprinted, sold, resold, copied, reproduced, redistributed, published, distributed, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA group of companies ("CLSA") and/or CLST.

CLSA and/or CLST have produced this publication/communication for private circulation professional, institutional and/or wholesale clients only. This publication/communication may not be distributed or redistributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. This is not intended to provide professional, investment or any other type of advice recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates or companies or individuals connected with CLSA /CLST may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that CLSA, CLST and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the discloseable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at http://www.clsa.com/member/research disclosures/. Disclosures therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company covered in this publication/communication, or from any third party in connection with this report. If investors have any difficulty accessing this website, please contact webadmin@clsa.com on +852 2600 8111. If you require disclosure information on previous dates, please contact compliance hk@clsa.com.

This publication/communication is distributed for and on behalf of CLSA Limited (for research compiled by non-US and non-Taiwan analyst(s)), and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd; in Hong Kong by CLSA Limited; in India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; SEBI Registration No: INZ000001735; in Indonesia by PT CLSA Sekuritas



Indonesia; in Japan by CLSA Securities Japan Co., Ltd; in Korea by CLSA Securities Korea Ltd; in Malaysia by CLSA Securities Malaysia Sdn Bhd; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST and in the United Kingdom by CLSA (UK).

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No.INM000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking securities and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com.

United States of America: Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

Canada: The delivery of this research report to any person in Canada shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in Canada wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

United Kingdom: In the United Kingdom, this research is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The research is disseminated in the EU by CLSA (UK), which is authorised and regulated by the Financial Conduct Authority. This document is directed at persons having professional experience in matters relating to investments as defined

in Article 19 of the FSMA 2000 (Financial Promotion) Order 2005. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where the research material is compiled by the UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules this research is prepared and intended as substantive research material.

Singapore: In Singapore, research is issued and/or distributed by CLSA Singapore Pte Ltd (Company Registration No.: 198703750W), a Capital Markets Services licence holder to deal in securities and an exempt financial adviser, solely to persons who qualify as an institutional investor, accredited investor or expert investor, as defined in s.4A(1) of the Securities and Futures Act. Pursuant to Paragraphs 33, 34, 35 and 36 of the Financial Advisers (Amendment) Regulations 2005 of the Financial Advisers Act (Cap 110) with regards to an institutional investor, accredited investor, expert investor or Overseas Investor, sections 25, 27 and 36 of the Financial Adviser Act (Cap 110) shall not apply to CLSA Singapore Pte Ltd. Please contact CLSA Singapore Pte Ltd (telephone No.: +65 6416 7888) in connection with queries on the report. MCI (P) 033/11/2016

The analysts/contributors to this publication/communication may be employed by any relevant CLSA entity, CLST or a subsidiary of CITIC Securities Company Limited which is different from the entity that distributes the publication/communication in the respective jurisdictions.

MSCI-sourced information is the exclusive property of Morgan Stanley Capital International Inc (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are service marks of MSCI and its affiliates. The Global Industry Classification Standard (GICS) was developed by and is



the exclusive property of MSCI and Standard & Poor's. GICS is a service mark of MSCI and S&P and has been licensed for use by CLSA.

 $\mbox{EVA}\mbox{\ensuremath{\mathbb{R}}}$ is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA and "CT" stands for CLST estimates unless otherwise noted in the source.